Recombinant SARS-CoV-2 Spike S1 抗体 (RBD)
-
- 抗原 See all SARS-CoV-2 Spike S1 抗体
- SARS-CoV-2 Spike S1
- 抗体类型
- Recombinant Antibody
- 片段
- single-domain Antibody (sdAb)
-
抗原表位
- RBD
-
适用
- SARS Coronavirus-2 (SARS-CoV-2)
-
宿主
-
Human
-
克隆类型
- 单克隆
-
标记
- This SARS-CoV-2 Spike S1 antibody is un-conjugated
-
应用范围
- ELISA, Neutralization (Neut), Colloidal Gold Immunochromatography Assay (GICA)
- 产品特性
-
This SARS-CoV-2 Spike RBD Nanobody is a recombinant monoclonal antibody generated through the expression of a DNA sequence inserting a human IgG1 Fc domain at the C-terminus, in human embryonic kidney 293 cells (HEK293). The DNA sequence encodes the SARS-CoV-2 spike receptor-binding domain (RBD). The antibody is purified by protein G in vitro. It has been validated with high reactivity towards SARS-CoV-2-S1-RBD by a functional ELISA and good sensitivity for human SARS-CoV-2 spike glycoprotein (S protein) via the Colloidal Gold Immunochromatography Assay (GICA). In neutralization assay, the binding signal of SARS-CoV-2 Spike RBD Nanobody was inhibited by ACE2 protein-HRP conjugated inhibitor, with a 0.1074 μg/mL IC50. Specifically binding and recognizing the RBD of the SARS-CoV-2 spike glycoprotein (S protein), so the SARS-CoV-2 Spike RBD Nanobody can react with samples infected with human coronavirus SARS-CoV-2. But it does not respond to MERS or SARS-CoV spike protein. Akin to other nanobodies, this recombinant nanobody is small and stable, which allows for its reaching to hidden epitopes such as crevices of target proteins.
VHH fusion with human IgG1 Fc - 纯化方法
- affinity-chromatography
- 免疫原
- Recombinant Human Novel Coronavirus Spike glycoprotein(S) (319-541aa)
- 克隆位点
- A1
- 亚型
- IgG1
- Featured
- Discover our best selling SARS-CoV-2 Spike S1 Primary Antibody
- Top Product
- Discover our top product SARS-CoV-2 Spike S1 Primary Antibody
-
-
- 应用备注
-
ELISA 1:10000-1:100000
GICA 1:10000-1:40000
Neutralising 1:100-1:10000 - 限制
- 仅限研究用
-
- 状态
- Liquid
- 缓冲液
- 50 % Glycerol, 0.01M PBS, pH 7.4, 0.03 % Proclin 300
- 储存液
- ProClin
- 注意事项
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 储存条件
- -20 °C,-80 °C
- 储存方法
- Upon receipt, store at -20°C or -80°C. Avoid repeated freeze
-
- 抗原
- SARS-CoV-2 Spike S1
- Abstract
- SARS-CoV-2 Spike S1 产品
- 别名
- E2 antibody, Surface Glycoprotein antibody, S antibody
- 物质类
- Viral Protein
- 背景
- Spike glycoprotein comprises two functional subunits responsible for binding to the host cell receptor (S1 subunit) and fusion of the viral and cellular membranes (S2 subunit). For many coronavirus (CoVs), S is cleaved at the boundary between the S1 and S2 subunits, which remain non-covalently bound in the prefusion conformation. The distal S1 subunit comprises the receptor-binding domain(s) and contributes to stabilization of the prefusion state of the membrane-anchored S2 subunit that contains the fusion machinery. S is further cleaved by host proteases at the so-called S2' site located immediately upstream of the fusion peptide in all CoVs. This cleavage has been proposed to activate the protein for membrane fusion via extensive irreversible conformational changes. However, different CoVs use distinct domains within the S1 subunit to recognize a variety of attachment and entry receptors, depending on the viral species. Endemic human coronaviruses OC43 and HKU1 attach via their S domain A to 5-N-acetyl-9-O-acetyl-sialosides found on glycoproteins and glycolipids at the host cell surface to enable entry into susceptible cells. MERS-CoV S uses domain A to recognize non-acetylated sialoside attachment receptors, which likely promote subsequent binding of domain B to the entry receptor, dipeptidyl-peptidase 4. SARS-CoV and several SARS-related coronaviruses (SARSr-CoV) interact directly with angiotensin-converting enzyme 2 (ACE2) via SB to enter target cells.
- 基因ID
- 43740568
- UniProt
- P0DTC2
-